美国FDA批准辉瑞和Merck两款Covid治疗药物，让病人在生病住院前可以在家服用。加拿大批准辉瑞抗病毒新药。

[贵圈]

美国食品药物管理局公布指出所有抗忧郁药都有增加年轻人自杀可能性的风险。一定要注意！

 

[BFB_GMAIL]

美国食品药物管理局公布指出所有抗忧郁药都有增加年轻人自杀可能性的风险。一定要注意！

这个不必自己操心, 医生就不肯给24岁以下开的, 除非有特殊情况。药剂师也把关的。

这里的医生, 即使你要求开药, 人家也不答应, 除非医生自己认为这是对的。

我个人估计, 您身体很健康, 很少有在加拿大求医问药的亲身体验, 只是凭想象很恐惧。如果您确实用过加拿大的医疗系统, 可能会增加信任。

 

[贵圈]

所以，这个抗抑郁药，还是救不了世界。巴西，小规模，30%的住院率下降。这数据，

加上抗抑郁药普遍的副作用。

怎么看都又是加拿大的一个大泡泡。

 

[BFB_GMAIL]

是的，每个药都不例外。

举例：

硫酸羟氯喹片说明书

眼器官疾病:

可发生视网膜色素沉着变化和视野缺损，罕有报道。早期停用本品后这些病变是 可逆的。如果进一步发展，即使停用本品后仍有加重的危险。报告有黄斑病变和 黄斑变性的病例，并且可能为不可逆。

视网膜病变的患者早期可能没有症状，或者伴有旁中心或中心环形暗点，暂时性 的盲点，颞侧视野缺损和异常色觉。

有角膜变化的报道包括角膜水肿和浑浊。可以无自觉症状或可引起诸如光晕、视 力模糊或畏光。这些症状可能是暂时的或停药后会逆转。

由于调节功能异常导致的视力模糊是剂量依赖的，也可能是可逆的。 皮肤及皮下组织类疾病:

皮肤及皮下组织类疾病:

有时可发生皮疹；搔痒症，皮肤粘膜色素变化、头发变白和脱发也有报道发生。 这些症状通常停药后容易恢复。

有大疱疹包括非常罕见的多形性红斑、Stevens-Johnson 综合症、中毒性表皮坏死 松解症、伴嗜酸性粒细胞增多和系统症状的药疹（DRESS 综合征）、光敏感和剥 脱性皮炎的报道。非常罕见的急性泛发性发疹性脓疱病（AGEP）病例，须与银 屑病进行区别，虽然羟氯喹可能促进银屑病的发作。发热和白细胞过多症可能与 羟氯喹有关。停药后通常结果好转。

胃肠系统疾病：

可出现胃肠道功能紊乱，例如恶心、腹泻、腹痛和呕吐。在减小剂量或停止治疗 后，这些症状通常会立刻消失。

神经系统疾病：

使用此类药物的不良反应如头晕、头痛、惊厥，均有报道。 锥体外系反应如肌张力障碍、运动障碍及震颤（见注意事项）。

精神疾病：

使用此类药物的不良反应如神经过敏和情绪不稳、精神病、自杀行为，均有报道。

耳及迷路类疾病：

使用此类药物的不良反应如眩晕、耳鸣、听觉缺失，均有报道。 肌肉骨骼及结缔组织疾病： 可发生感觉运动神经疾病。有进行性虚弱和近端肌群萎缩的骨骼肌肌病或神经 肌病的报道。停药后肌病可能恢复 ，但恢复需多个月。 可能观察到伴有轻微的感觉变化，腱反射抑制和异常神经传导。

心脏器官疾病：

存在特殊风险因素的患者中的 QT 间期延长，可能导致心律失常（尖端扭转型室 性心动过速、室性心动过速）（参见注意事项）。

心肌病（可能导致心力衰竭），一些病例报告了死亡。

当发现有心脏传导异常（束支传导阻滞/房室传导阻滞）及双侧心室肥大时，应 怀疑到药物的慢性毒性。停药后可能恢复。

血液及淋巴系统疾病：

骨髓抑制的报道比较罕见。血液学的异常如贫血、再生障碍性贫血、粒性白细胞 缺乏症，白细胞减少症和血小板减少症都曾有报道。

羟氯喹可能会促使或加重卟啉症。

肝胆疾病：

有肝功能检测异常的个例报道，并有一些暴发性肝功能衰竭的病例报道。

免疫系统疾病：

荨麻疹、血管性水肿和支气管痉挛均有报道。 代谢及营养类疾病： 常见厌食。可能发生低血糖症，频率未知。

代谢及营养类疾病：

常见厌食。可能发生低血糖症，频率未知。

https://www.sanofi.cn/-/media/Project/One-Sanofi-Web/Websites/Asia-Pacific/Sanofi-CN/Home/high-quality-products/prescription/2021014_Plaquenil-tab-02g-LRL-transferred.pdf?la=zh&hash=731DB31E526B0EE487DC2E2637F5FC7F

是的, 如果遵医嘱正当服用羟氯喹, 本来是很安全的。但是如果搜一下, 也会被搜出一长串副作用。这是由于制药业的严谨。药物要遵医嘱, 有疑虑要问医生问药剂师的专业意见。

 

[贵圈]

世卫组织数据库

Fluvoxamine contains the active ingredient(s): Fluvoxamine.
Result is presented for the active ingredient(s).
Total number of records retrieved: 10306.

ivermectin contains the active ingredient(s): Ivermectin.
Result is presented for the active ingredient(s).
Total number of records retrieved: 5697.、

 

[贵圈]

 

[贵圈]

对比一下，IVM历史用量远远大于F。
IVM有效性略低，但是数据量大得多。可靠性高得多。
IVM可以预防性使用，F不可以
IVM安全性比F高出很多，事故少很多。（一半)

 

[BFB_GMAIL]

预防性使用，F不可以

F的确不可以预防新冠。

所以, 不要号召没有得新冠的人去找医生开药了。医生不会给开的。疫情期间, 大家还是尽量少给医生添乱吧。

 

[贵圈]

预防目前就IVM，HCQ效果不如IVM。

所谓双强关联。IVM要是早在北美铺开，何至于此。

 

[BFB_GMAIL]

感觉象一场宫斗大戏。
1、疫苗是三千宠爱在一身, 独擅专房
2、 IVM和HCQ姐妹花, 要上位平分秋色。
3、正在这时, 有Fluvoxamine进宫。那别管她将来是否真能得宠, 也先把她干掉再说。

不提新药打压老药的阴谋论了, F也是老药。本来是话术, 只为IQ上位, 有谁还真管它新老。污名F, 无非也是为IQ上位。

 

[贵圈]

这里面还有一个恶毒的太后，对IVM百般欺凌。一心想把M搞进来。

 

[贵圈]

疫情虚无主义啊，实际上IVM救了很多国家，但是美国愣是宁死不救。这宫斗后面全是人命。恶。

 

[lindamy]

UK authorizes Merck antiviral pill, 1st shown to treat COVID​

By MATTHEW PERRONE and MARIA CHENGtoday


1 of 2
FILE - This undated image provided by Merck & Co. shows their new antiviral medication against COVID-19. Britain has granted a conditional authorization to Merck's coronavirus antiviral, the first pill shown to successfully treat COVID-19. It is the first country to OK the treatment, although it was not immediately clear how quickly the pill would be available. (Merck & Co. via AP, File)

LONDON (AP) — Britain granted conditional authorization on Thursday to the first pill shown to successfully treat COVID-19 so far. It also is the first country to OK the treatment from drugmaker Merck, although it wasn’t immediately clear how quickly the pill would be available.

The pill was licensed for adults 18 and older who have tested positive for COVID-19 and have at least one risk factor for developing severe disease, such as obesity or heart disease. Patients with mild-to-moderate COVID-19 would take four pills of the drug, known molnupiravir, twice a day for five days.

An antiviral pill that reduces symptoms and speeds recovery could prove groundbreaking, easing caseloads on hospitals and helping to curb outbreaks in poorer countries with fragile health systems. It would also bolster the two-pronged approach to the pandemic: treatment, by way of medication, and prevention, primarily through vaccinations.

Molnupiravir is also pending review with regulators in the U.S., the European Union and elsewhere. The U.S. Food and Drug Administration announced last month it would convene a panel of independent experts to scrutinize the pill’s safety and effectiveness in late November.

Initial supplies will be limited. Merck has said it can produce 10 million treatment courses through the end of the year, but much of that supply has already been purchased by governments worldwide.

In October, U.K. officials announced they secured 480,000 courses of molnupiravir and expected thousands of vulnerable Britons to have access to the treatment this winter via a national study.

“Today is a historic day for our country, as the U.K. is now the first country in the world to approve an antiviral that can be taken at home for COVID-19,” British health secretary Sajid Javid said.

“We are working at pace across the government and with the NHS to set out plans to deploy molnupiravir to patients through a national study as soon as possible,” he said in a statement, referring to the U.K.’s National Health Service. Doctors said the treatment would be particularly significant for people who don’t respond well to vaccination.

Merck and partner Ridgeback Biotherapeutic have requested clearance for the drug with regulators around the world for adults with early cases of COVID-19 who are at risk for severe disease or hospitalization. That’s roughly the same group targeted for treatment with infused COVID-19 antibody drugs, the standard of care in many countries for patients who don’t yet require hospitalization.

Merck announced preliminary results in September showing its drug cut hospitalizations and deaths by half among patients with early COVID-19 symptoms. The results haven’t yet been peer reviewed or published in a scientific journal.

The company also didn’t disclose details on molnupiravir’s side effects, except to say that rates of those problems were similar between people who got the drug and those who received dummy pills.

The drug targets an enzyme the coronavirus uses to reproduce itself, inserting errors into its genetic code that slow its ability to spread and take over human cells. That genetic activity has led some independent experts to question whether the drug could potentially cause mutations leading to birth defects or tumors.

Britain’s Medicines and Healthcare products Regulatory Agency said molnupiravir’s ability to interact with DNA and cause mutations had been studied “extensively” and that it wasn’t found to pose a risk to humans.

“Studies in rats showed that (molnupiravir) may cause harmful effects to the unborn offspring, although this was at doses which were higher than those that will be given to humans, and these effects were not observed in other animals,” the agency said in an email.

In company trials, both men and women were instructed to either use contraception or abstain from sex. Pregnant women were excluded from the study. Merck has stated that the drug is safe when used as directed.

Molnupiravir was initially studied as a potential flu therapy with funding from the U.S. government. Last year, researchers at Emory University decided to repurpose the drug as a potential COVID-19 treatment. They then licensed the drug to Ridgeback and partner Merck.

Last week, Merck agreed to allow other drugmakers to make its COVID-19 pill, in a move aimed at helping millions of people in poorer countries get access. The Medicines Patent Pool, a U.N.-backed group, said Merck will not receive royalties under the agreement for as long as the World Health Organization deems COVID-19 to be a global emergency.

But the deal was criticized by some activists for excluding many middle-income countries capable of making millions of treatments, including Brazil and China.

Still, experts commended Merck for agreeing to widely share its formula and promising to help any companies who need technological help in making their drug — something no coronavirus vaccine producers have agreed to.

“Unlike the grotesquely unequal distribution of COVID-19 vaccines, the poorest countries will not have to wait at the back of the queue for molnupiravir,” said Dr. Mohga Kamal-Yanni, a senior health adviser to the People’s Vaccine Alliance. Fewer than 1% of the world’s COVID-19 vaccines have gone to poor countries and experts hope easier-to-dispense treatments will help them curb the pandemic.

Merck previously announced licensing deals with several Indian makers of generic drugs to manufacture lower-cost versions of molnupiravir for developing countries.

The U.S. has agreed to pay roughly $700 per course of the drug for about 1.7 million treatments. Merck says it plans to use a tiered pricing strategy for developing countries. A review by Harvard University and King’s College London estimated the drug costs about $18 to make each 40-pill course of treatment.

While other treatments have been cleared to treat COVID-19, including steroids and monoclonal antibodies, those are administered by injection or infusion and are mostly used in hospitals and other health care facilities.

LONDON (AP) — Britain granted conditional authorization on Thursday to the first pill shown to successfully treat COVID-19 so far. It also is the first country to OK the treatment from drugmaker Merck, although it wasn't immediately clear how quickly the pill would be available.

 

[lindamy]

辉瑞正在做实验的治疗药物

The pill, still known by its experimental name PF-07321332, is what's known as a protease inhibitor.

Pfizer says its experimental pill reduces risk of hospitalization, death from Covid-19

Drugmaker Pfizer said Friday its experimental pill designed to fight coronavirus reduced the risk of hospitalization and death for high-risk patients taking part in a trial of the drug.

www.cnn.com

 

[廊坊头条]

这儿有一个辉瑞的中文的：

辉瑞宣布：抗新冠口服药死亡风险降低近90% - 人在温哥华网 VanPeople.com

辉瑞公司周五宣布，其针对 COVID-19的实验性抗病毒药丸将住院率和死亡率降低了近 90%。辉瑞表示，将要求 FDA 和国际监管机构尽快批准其药丸。专家之前根据该药的实验强度，已

info.vanpeople.com

辉瑞实验数据
辉瑞周五公布了对 775 名成年人的研究的初步结果。 与服用假药丸的患者相比，服用该公司药物和另一种抗病毒药物的患者在一个月后的住院或死亡综合率降低了 89%。 服用该药的患者中只有不到 1% 需要住院治疗，并且没有人死亡。 在对照组中，7% 的人住院，7 人死亡。
辉瑞首席科学官 Mikael Dolsten 博士在接受采访时说：“我们希望我们有一些非凡的东西，但你很少看到伟大的药物具有近 90% 的疗效和 100% 的死亡保护。”